Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

Inclusion Criteria: * age \> 18 years * B-ALL in relapse * refractory B-ALL-performance status of 0-2 on the Eastern Cooperative Oncology Group scale * adequate hepatic and renal functions (AST or ALT \<= 5 times the upper limit of normal creatinine \< 2 times the upper limit of normal) * \> 20% blasts in bone marrow, * \> 30% of bone marrow blast population HER2 positive as assessed by immunophenotyping Exclusion Criteria: * Previous treatment by trastuzumab * FEVG \< 50%